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Abstract 
Objective 
To investigate efficacy, patient acceptability and feasibility of formulation-based cognitive behavioural 
therapy (CBT) for adults with attention deficit hyperactivity disorder (ADHD).  NICE guidelines for adult 
ADHD recommend further research into psychological treatments.   
Method 
60 participants with adult ADHD were randomly allocated to treatment as usual (TAU) vs TAU plus up to 
16 sessions of individual formulation-based CBT for ADHD.   
Results 
Adding formulation based CBT to TAU for ADHD significantly improved ADHD symptoms on the Barkley 
Current Symptoms Scale and scores on the Work and Social Adjustment Scale.  Adjusted effect sizes (ES) 
were 1.31 and 0.82 respectively.  
There were also significant improvements on secondary outcomes including independently evaluated 
clinical global improvement, self-rated anxiety, depression, global distress and patient satisfaction 
(adjusted effect sizes 0.52-1.01). 
Conclusions 
This is the first randomized controlled trial to provide preliminary evidence of efficacy and acceptability of 
individual formulation-based CBT for ADHD when added to TAU over TAU alone.  This approach now 
needs to be tested in a larger multi-centred randomized controlled trial. 
Keywords: randomized controlled trial, adult, attention deficit disorder with hyperactivity, cognitive 
therapy 
Running head: cognitive behavioural therapy for adult ADHD 
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Significant Outcomes 
This is the first clinical trial to provide evidence of the effectiveness of individually delivered formulation-
based cognitive-behavioural therapy for adult ADHD. 
When added to treatment as usual, cognitive behavioural therapy had significantly greater success in both 
reducing ADHD symptoms and improving occupational and social functioning than treatment as usual 
alone. 
Limitations 
A high number of participants in the TAU group were lost to follow-up.  However the sensitivity analysis 
suggests that even when taking this into consideration, the treatment effect was robust. 
The study design does not control for therapist time and attention. 
We excluded participants with an alternative primary diagnosis or severe co-morbidities which could 
affect the generalisability of the findings.  This was because we wanted the CBT to focus on ADHD and 
associated problems as opposed to a separate primary clinical problem.  However individualised 
formulation can be complex so it seems likely this approach, which has been shown to be effective in 
reducing emotional distress, could be adapted for people with ADHD who have severe co-morbidities.   
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Introduction  
While medication remains the first line of treatment for attention deficit hyperactivity disorder (ADHD) in 
adults, National Institute for Health and Care Excellence (NICE) guidelines for the condition (1) recommend 
that medication be complemented by cognitive behaviour therapy (CBT) and that further research focus 
on developing psychological treatments.  Most studies have investigated group treatments, and indeed on 
the basis of current evidence NICE recommends these as they are most cost-effective.  However ADHD 
presentations tend to vary widely and, even though many of the group approaches use individual 
coaches/support persons to help participants apply the skills to their own difficulties, group treatments 
provide less flexibility than individualised therapies to address idiosyncratic difficulties. Indeed a recent 
study found that a highly structured group intervention specifically developed to address ADHD-related 
difficulties did not outperform individual non-specific counselling and this may have been one of the 
reasons (2). 
 
There have been four randomized controlled trials of individualised CBT that are structured and 
manualised (3-6).  All found that CBT reduced ADHD symptoms (self and independently rated) compared 
with the control treatment(s).  However in the Virta study whilst some encouraging improvements were 
seen in the CBT condition, most results were not statistically significant.  Safren et al’s studies used larger 
samples and longer interventions and moderate to large effect sizes were found on the primary outcomes.  
The Weiss et al study compared CBT plus placebo with CBT plus medication.  Both groups showed 
statistically significant improvements in symptoms and functioning between baseline and the outcome 
points.  The approaches in both the Safren and Weiss studies were similar in that they were modular and 
behavioural in nature and neither appeared to use  ‘Beckian’ individualised case formulations to guide the 
treatment.   
 
Uncontrolled studies have used individualised case formulations to tailor the CBT for ADHD (7, 8).  These 
authors have described models derived from Beck’s cognitive therapy (9) in which the core ADHD 
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symptoms contribute to the development of negative underlying beliefs (dysfunctional assumptions and 
core beliefs) and maladaptive coping strategies.  While results are promising, there is as yet no 
randomized controlled trial evaluating this approach.  The advantage of individualised case formulation is 
that central themes binding apparently disparate problems or symptoms can be identified, enhancing 
clients’ understanding (and hence engagement) and allowing techniques to be directly targeted.  The 
formulation based approach has greater flexibility to focus specifically on the patient’s key presenting 
difficulties.  It can be both ADHD-specific and at the same time address associated emotional disorders 
which may have a reciprocal maintaining relationship with the ADHD symptoms.  The primary aim of the 
current study was therefore to investigate efficacy, patient acceptability and feasibility of a formulation-
based cognitive behavioural therapy for adults with ADHD (10).  It was hypothesised that CBT plus 
treatment as usual would be more effective than TAU alone in i) reducing ADHD symptoms and ii) 
improving functioning at 42 weeks after the start of the study (12 weeks post-active CBT treatment).   
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Methods 
This RCT was approved by the City Road and Hampstead Research Ethics Committee (reference 
09/H0721/49) and registered as a controlled trial (ISRCTN 03732556).  Participants were recruited from a 
specialist adult ADHD clinic between April 2010 and June 2013.  They were included in the trial if they i) 
gave written informed consent ii) were 18-65 years of age, iii) had been diagnosed with adult ADHD (with 
childhood onset) by a mental health professional, iv) scored 6 or more on either the inattentive or the 
hyperactive/impulsive subscale of the Adult Barkley Current Symptoms Scale (self-rated) (11)and v) were 
rated to have at least moderate clinical severity as indicated by a score of 4 or more on the Clinical Global 
Impression scale (12). 
Participants were excluded if i) ADHD was not the dominant clinical diagnosis, i.e. they had a 
clinically significant anxiety disorder and/or current episode of major depression, significant risk of self-
harm, active substance misuse/dependence in the last three months, an acquired brain injury, primary 
diagnosis of psychosis or bipolar disorder, a pervasive developmental disorder, a previous diagnosis of a 
personality disorder or any other dominant clinical diagnosis whereby participation in the trial would be 
inappropriate for their clinical needs and/or where treatment of the primary disorder was warranted; ii) 
they had a verbal IQ of less than 80; iii) they were unable to meet the requirements of an RCT (e.g. not 
able to attend regularly and reliably for sessions); iv)  they were currently undergoing another talking 
therapy for ADHD or any other psychiatric disorder; v) they were unable to speak English at an adequate 
level to participate; vi) if on medication, they were stabilised on the medication type and dose for less 
than three months.  However the latter criterion was removed several months into the trial with the 
agreement of the Trial Steering Committee (TSC) in a bid to improve recruitment rates.  The TSC advised 
that the randomized controlled design would control for any differences in medication between the two 
groups. 
8 
 
Diagnosis of adult ADHD was confirmed using adult symptoms in the Conners’ Adult ADHD Diagnostic 
Interview for DSM IV (CAADID) (13).  Presence of other co-morbid conditions was assessed using the Mini-
International Neuropsychiatric Interview (MINI) (14).   
Interventions  
For brevity, the two treatments will be referred to as CBT and TAU rather than CBT plus TAU and TAU 
alone. 
Treatment as usual   
All participants in the trial received TAU.  This included visits to their clinic doctor in the service, if 
applicable, or visits to their local specialist ADHD service, community mental health team (CMHT) or 
general practitioner (GP) for management of their ADHD.  All TAU sessions focused on medication 
management and related issues such as side-effects.  It was verified at research visits that participants 
were not given information or advice with regard to psychosocial strategies to manage their ADHD 
symptoms.  There was no additional therapist involvement.   
CBT  
In addition to TAU, participants randomized to CBT attended up to 15 CBT sessions over 30 weeks.  They 
had a sixteenth, follow-up, CBT session at 42 weeks (just prior to the main outcome point).  A CBT manual 
was developed and updated iteratively.  We hope to be able to make this available in the near future.  
Treatment was divided into four stages.   
During stage 1 (engagement and treatment planning; sessions 1-3), information was given about adult 
ADHD and a shared formulation derived.  The formulation made links between the individual’s 
predisposition (i.e. vulnerability factors such as genetic make-up and personality), early life experiences 
and current coping behaviours and cognitions.  Goals for treatment were agreed.   
Stage 2 (active treatment; sessions 4-13), involved working towards the goals, in particular focusing on the 
problematic cognitions and behaviours identified in the assessment and initial formulation.  Earlier 
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sessions focused on problem-solving and adaptive skills such as time management and organisation, 
where indicated by the goals and formulation. Cognitive techniques such as thought challenging and 
behavioural experiments were used to question and test unhelpful beliefs.  Guidance was provided on 
managing impulsivity and unhelpful emotional responses.  A detailed longitudinal formulation was 
developed identifying key core beliefs, rules for living, unhelpful compensatory strategies and their 
effects.  Explicit links were made between these and ADHD-related difficulties. For example, a participant 
held beliefs about not being good enough as they had been criticised throughout their life for being 
disorganised. They had coped by avoiding responsibilities which compounded their underlying beliefs.  A 
new formulation with new core beliefs, rules for living and helpful coping behaviours was then derived.  
Participants found evidence for their new beliefs by experimenting with the new coping behaviours. 
In stage 3 (preparation for the future; sessions 14 and 15), participants completed a ‘blueprint for 
therapy’, recording what they had learned and how to continue to implement these changes in the future.  
Goals for treatment were re-rated. 
Stage 4 (follow-up; session 16), took place just prior to 42 weeks from baseline. Participant and therapist 
reviewed any change since the end of active treatment, re-rated goals, identified any further gains made 
and discussed management of any setbacks.   
Throughout, treatment was adapted for ADHD with emphasis on agenda setting, staying on-task during 
sessions, rehearsal of adaptive coping skills, problem-solving any ADHD-related therapy interfering 
behaviour (such as non-completion of homework, arriving late or forgetting sessions) and revisiting the 
individual’s history in linking current beliefs and behaviour with early life experiences. 
The treating therapists were a clinical psychologist and a counselling psychologist who both had 
experience in treating ADHD in adults.  One psychologist (MS) treated 5 of the CBT cases whilst the other 
(AD) treated 25. A senior CBT therapist provided joint supervision. 
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A number of common themes emerged which were very similar to those previously described by other 
authors (15).  Schema included self-mistrust, failure, incompetence, inadequacy and instability.  Examples 
of core beliefs included ‘I am irresponsible/unreliable’, ‘I am not good enough’, ‘I am ineffective’, ‘I am 
inferior to others/worthless’, ‘I am out of control’.  These appeared to be related to the individual’s 
experiences such as criticism from significant others, experiencing cognitive difficulties in comparison with 
peers, traumatic early life experiences (such as neglect or abuse) and ‘over-protective’ parenting.  Similar 
common compensatory strategies to those previously described were also observed including anticipatory 
avoidance/procrastination, brinksmanship, juggling, pseudoefficiency and stoicism.  In addition, the 
following were also seen: withdrawal, ignoring/suppressing own needs and emotions, verbal 
intimidation/aggression, perfectionism/setting unrealistic goals and rumination. 
  
Outcome measures 
The assessments described below were administered at three time points: baseline (pre-treatment), 30 
weeks (post treatment for the CBT condition) and 42 weeks (12 week follow-up for the CBT condition).  
The main outcome was at 42 weeks assessment.  All assessments were carried out by an assistant 
psychologist.  In addition, at weeks 30 and 42, an independent assessor (mental health professional in the 
same NHS trust), blind to treatment group, interviewed the participants and rated their clinical 
improvement and current functioning.  
In order to address the validity of the blinding procedure, blind assessors were asked to complete a 
questionnaire at each assessment point noting the treatment group that they thought the participant was 
in and if this was (a) a guess, (b) revealed by the participant, or (c) due to another reason (which they were 
asked to state). Of the treatment completers, blind assessors were accurate in their assignment of 
treatment group in 21 (78%) of cases. Two (7%) participants ‘unblinded’ the assessor to treatment group 
(i.e., the assessor cited (b) as the reason for their choice of treatment group) and the blind assessor’s 
described their choice as a ‘guess’ in 24 (89%) of cases. In one (4%) of the cases, the assessor cited (c) as 
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the reason for group assignment stating that the participant had referred to the fact that being in the trial 
had ‘helped him cope with his difficult personal circumstances’. 
Primary outcome measures 
Two primary outcomes were included.  The first, the Adult Barkley Current Symptoms Scale (CSS) (11) 
includes questions assessing the frequency of the 18 DSM-IV ADHD symptoms; 9 inattentive and 9 
hyperactive/impulsive symptoms on a scale ranging from 0 = “never or rarely” to 3 = “often”, with a score 
of 2 or above indicating presence of a symptom.  A total score (maximum 54 points) is derived by summing 
all items in both categories, alternatively a subscale can be derived for the two constructs. We chose to 
use the total ADHD score.  This measure has strong reliability and validity and has been widely used in 
ADHD research. Norms are available for clinically significant thresholds (16).    
The other primary outcome was the Work and Social Adjustment Scale (WSAS) (17)which measures 
impairment in functioning in relation to a specific problem, in this case the participant’s ADHD symptoms.  
It consists of 5 questions each rated on an 8-point scale (0 = “not at all impaired” and 8 = “very severely 
impaired”).  Reliability and validity of this scale has not been specifically investigated in adult ADHD. 
However studies in other conditions (depression and OCD) suggest that a score of 20 or more indicates 
moderately severe or worse psychopathology. Scores of 10 to 20 are associated with significant functional 
impairment but less severe clinical symptomatology and scores below 10 are associated with subclinical 
populations. 
Secondary outcome measures 
Self-report measures included the Hospital Anxiety and Depression Scale (HADS) (18), the Clinical 
Outcomes in Routine Evaluation Outcome measure (CORE-OM) (19), the Clinical Global Impression scales, 
Improvement and Satisfaction versions (CGI) (12, 20).  CGI scales were recoded as binary variables from 
their original 5 point scale. CGI improvement was coded as improved if participants felt “very much 
better” or “much better” and not improved otherwise. Participants were coded as satisfied if they 
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responded “very satisfied” or “moderately satisfied” and not satisfied otherwise. The independent (blind) 
assessor was also asked to complete the CGI Improvement scale which was recoded as binary in the same 
way as the self-report scale.  The evaluator based their CGI ratings on a semi-structured interview 
(included in the supplementary information) that was devised by the research team asking a number of 
open-ended questions about the participant’s symptoms and functioning.  Finally an informant – a person 
who knew the participant well such as parent or spouse – was asked to complete the informant version of 
the CSS (11).  
Randomisation  
Participants were randomized to one of the two groups using sequence generated randomisation tables 
and fixed length blocks (length concealed), stratified for gender. Randomisation was performed by an 
independent group in another service in the same NHS trust using a concealed sequence.  The 
independent statistician and the independent assessor who assessed the participants at weeks 30 and 42 
were both blind to the treatment allocations. 
 
Treatment fidelity 
All CBT cases were recorded to assess treatment fidelity.  A proportion (25%; 8 recordings) of cases of 
session 4 were randomly selected and rated by two independent therapists outside of the clinical trial as 
to overall therapeutic alliance and the extent to which the therapist adhered to the manual (7-point Likert 
scales).  The raters co-rated 50% of the recordings to establish inter-rater reliability.  Therapists’ 
adherence to the manual and therapeutic alliance median scores were high (both 6/7).   
  
Statistical methods 
Sample Size 
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The sample size calculation was based on a previous study by Safren et al (2005) which compared CBT plus 
continued medication with continued medication only.  This study found the change score of the mean 
was 9.  A sample size of 23 in each group would be needed to have 90% power to detect a difference of 
this size with an α level of 0.05.  To account for dropout, recruitment was aimed at 30 participants per 
group. 
Statistical analysis plan 
Prior to analysis, a statistical analysis plan was agreed with the Trial Steering Committee (TSC). Analysis 
was intention to treat and linear mixed effect models were used to analyse the primary outcomes, mean 
group differences for CSS and WSAS at 42 weeks. Both 30 and 42 week scores were included in the 
analysis model, with an interaction between treatment and time to allow treatment estimates to differ at 
30 to 42 weeks. Outcomes were adjusted for baseline outcomes scores and age as fixed effects.  To 
account for correlations between repeated measures within participants, analysis models included a 
random intercept. 
Before the analysis plan was finalised, secondary outcome measures were selected.  Secondary outcomes 
at 42 weeks were fit using similar models where these outcomes were continuous. It was intended to use 
mixed effects logistic regression for the binary clinical global improvement and satisfaction outcomes. 
However, the small number of events in the control group meant that treatment estimates were unstable 
and thus Fisher’s exact test was used instead. Group differences in adverse events were compared with 
Fisher’s exact test, both by person and event as 3 people had more than 1 adverse event.  
The following procedures were used to deal with missing data. Where 75% or more questions were 
answered on a single questionnaire, missing answers were imputed with the mean of remaining answers 
on that questionnaire for that participant. Otherwise that particular questionnaire outcome for that 
participant was treated as missing. Two approaches were used to deal with missing outcome data. Firstly, 
the main analysis used mixed effects models fit using maximum likelihood (ML). These models allow all 
available data to be included in the analysis, under the assumption that data is missing at random (MAR), 
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that is predictors of baseline missingness being included in the model. No baseline predictors of 
missingness were found (using logistic regression and Fisher’s exact test). In addition, the MAR assumption 
was explored in a sensitivity analysis in which values of missing primary outcome scores were imputed 
which would change the clinical interpretation of the effect (21). The degrees of freedom for statistical 
tests and confidence intervals were derived using the Kenward-Rogers approximation.  Both adjusted and 
unadjusted mean treatment effects were reported, with 95% confidence intervals and significance levels 
for adjusted treatment effects and effect size (Hedges g) for unadjusted effects. All analyses were done in 
R v 3.0.3 with the packages lme4 and pbKRtest. 
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Results 
Participant Flow 
Figure 1 about here 
Figure 1 shows participant flow from screening to follow-up.  The main reasons for not participating were 
not meeting the study criteria (n=929) and declining to participate (n=139).  The reasons for not meeting 
the study criteria were: outside the age limit (n=9), not diagnosed with adult ADHD (n=83), CSS or CGI 
score too low (n=88), ADHD not the primary diagnosis (n=596), verbal IQ of less than 80 (n=32), unable to 
meet the requirements of an RCT (n=63), currently undergoing or on the waiting list for another talking 
therapy (n=45), not stabilised on medication (n=13; with agreement from the TSC this criterion was 
removed a few months into the trial, to maximise recruitment).  
60 people who met study criteria and gave written informed consent were randomized to either TAU 
(n=30) or CBT (n=30). 
In the TAU group one participant did not receive the allocated intervention deciding to take up routine 
(non-trial) CBT sessions in the service. However the participant remained in the trial for the research 
assessment follow-up.  Two people in the TAU group discontinued the intervention and withdrew from 
the trial: one because they were unhappy at being allocated to TAU and another had a change in personal 
circumstances.  A further nine were lost to follow-up.  In the CBT group, two people discontinued the 
intervention: one did not think CBT was needed and another discontinued due to a change in personal 
circumstances.  A further one was lost to follow-up.  There was a significantly higher loss to follow-up for 
TAU (13 for primary outcome) than CBT (3 for primary outcome).  A full presentation follows below in the 
missing data section.  
People in the CBT group attended a mean of 1.2 (SD 2.0) ADHD medical appointments over the period of 
the trial while people in the TAU group attended a mean of 1.8 (SD 2.9).  There was no significant 
difference between the two groups.  Almost all trial completers in the CBT group attended all 16 CBT 
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sessions offered, only two trial completers missed sessions; one participant missed three sessions and one 
missed two.  (Due to potential erratic attendance, therapists were flexible in rescheduling CBT 
appointments so that all 16 sessions could be attended wherever possible in the necessary timescale; if 
the session was going to  be missed all together, on rare occasions a telephone appointment was offered 
instead). 
Participant characteristics and baseline medication 
The 60 participants were well balanced on age, ethnicity, education and marital status (see table 1). There 
were 7 more men in the CBT group than TAU but the authors are not aware of any evidence to suggest 
that there are gender differences in response to CBT treatment. Clinically at baseline the two groups were 
very similar in terms of ADHD symptoms (CAADID and CSS). They were also similar in terms of medication 
use: 24 participants in the CBT group were stable with regard to medication status (either not taking it at 
all or on the same medication type and dose) for three months or more at baseline, versus 22 in the TAU 
group.  In terms of ADHD medication, 19 participants in the CBT group were on ADHD medication versus 
26 in the TAU group; in terms of other psychotropic medication, 8 participants in the TAU group were on 
SSRIs versus 2 in the CBT group. One participant in the CBT group was taking a benzodiazepine (see Table 
2). Both groups were also similar in terms of anxiety and depression scores. Taking 11 as the threshold on 
each subscale on the HADS, 14 were in the moderate to severe anxiety range in each group. One person in 
the CBT group vs 4 people randomized to TAU were in the moderate to severe depression range.  
  
Primary Outcomes 
The results of the analysis are summarised in figures 2a and 2b table 3. 
CSS: The CBT group showed a large improvement in both primary outcomes relative to the TAU group. At 
42 weeks, the treatment difference for CSS scores was 8.8 points lower in the CBT group relative to TAU, 
(standardised ES = -1.31, p < 0.001). Checking the robustness of the results using Markov Chain Monte 
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Carlo sampling, similar estimates were obtained with a treatment effect of 8.74 (95% Bayesian Credible 
Interval: 5.0 to 13.3). At 30 weeks the effect of treatment was marginally larger (ES: -1.52, p < 0.001) 
WSAS: Similarly the WSAS scores were 6.6 points lower in the CBT group than TAU, (standardised ES = -
0.82, p = 0.003). Similarly a MCMC model estimated the group difference as 6.44 points (95% BCI: 3.2 to 
10.3). At 30 weeks the standardised ES was identical (ES = -0.82, p = 0.002) 
Secondary Outcomes 
CGI:  Only small numbers of participants improved in the TAU group compared to the CBT group and thus 
the inferential statistics are not particularly informative but presented for completeness. The odds ratio 
(OR) for participant rated CGI Improvement for CBT vs TAU was 23.1 (p < 0.001). For CGI Satisfaction the 
OR was 23.2 (p < 0.001). For blind assessors the OR was not computable as 0 participants were rated as 
improved in the TAU group. 
CSS Informant: There was a moderate but non-significant benefit of CBT at 42 weeks (standardised ES = -
0.38) and 30 weeks (ES = -0.42)  
HADS:  HADS anxiety scores were lower at 42 weeks (ES = -0.6, p = 0.012) and at 30 weeks (ES = -0.62, p = 
0.015) for CBT vs TAU. Similarly, HADs depression scores were lower at both 42 weeks (ES = -0.66, p = 
0.002) and 30 weeks (ES = -0.61, p = 0006).   
CORE:  For CORE sub-domains, the CBT group improved across all domains relative to TAU at both 42 and 
30 weeks, although only Problems and Wellbeing showed a statistically significant decrease.  The decrease 
was moderate for Problems (42 weeks, ES = -0.59, p = 0.025 and 30 weeks, ES = -0.58, p = 0.023), and large 
for Wellbeing (42 weeks ES = -1.03, p = 0.02; 30 weeks ES = -1.01, p = 0.02). For CORE Functioning and 
Risk, effects were small, below 0.3 at both 30 and 42 weeks (see Table 3). 
Safety data and changes in ADHD medication through the course of the trial 
There were eight adverse events for five people in the CBT group and three events for three people in the 
TAU group.  Neither of these differences was significant, either by person (p = 0.99) or by symptom (p = 
18 
 
0.49). Only two of the events, both of which were in the CBT group, were deemed to be serious, as they 
required unplanned hospital treatment and these were both rated as ‘definitely unrelated’ to the trial.  
Further details of the adverse events are provided as supplementary data. 
CGI Improvement rated by participants showed little association with changes in ADHD medication for 
each group at 30 weeks or 42 weeks. For those who improved at 42 weeks, only one person in the TAU 
group and no one in the CBT group changed medication between baseline and 30 weeks. From 30 to 42 
weeks, three improvers in the CBT group and one improver in the TAU group changed their medication.  
Of these, two in the CBT group changed the type of their medication, whilst one in each group decreased 
medication. 
Missing data and sensitivity analysis 
More people were lost to follow-up in the TAU arm relative to the CBT arm. For the primary outcomes 
three out of 30 outcomes were missing in the CBT group versus 13 out of 30 in the TAU group, (OR  0.15, 
Fisher’s exact test, p = 0.007). The relative difference in drop-out between groups suggests that 
missingness is non-ignorable and so a sensitivity analysis was undertaken in which values were imputed 
for the missing observations for the CSS based on particular scenarios. We focused on changes to the 
point estimate of the treatment difference as adding observations will lead to smaller standard errors due 
to increased sample size, but included confidence intervals as an approximation to likely interval 
estimates. In the first scenario we assumed scores for all participants who dropped out returned to their 
baseline level. This had little impact on the treatment difference with the advantage for the CBT group 8.8 
(95% CI: 4.8 to 12.8 points on the CSS). In the second scenario we explored non-ignorable missingness. As 
we were interested in the conditions which would lead to eliminating the treatment effect, this might 
involve drop-out in the CBT arm being associated with worse outcomes and those in the TAU arm with 
better outcomes. If we assume that dropouts in the TAU arm returned to baseline and CBT dropouts had 
the worst possible outcome (a maximum score of 54 on the CSS) the treatment difference was 7.3 (95% CI: 
2.7 to 12.1). In the third scenario we assumed CBT dropouts returned to their baseline score and derived 
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the improvement necessary in the TAU dropouts in order for the 95% confidence interval to include 0.  An 
improvement of 12 points for the dropouts in the TAU group meant the 95% CI included 0, treatment 
difference at 3.49 (95% CI: 0.1 to -7.1) in favour of the CBT group. We infer that our results are robust 
given that these scenarios are quite implausible.   
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Figure 2. Estimated means and 95 % confidence intervals by treatment group and time point (0, 30 
and 42 weeks) for the CSS and WSAS. Confidence intervals are derived from the primary analysis 
models, with outcomes by treatment group adjusted by time, time by treatment group interaction and 
adjusted for baseline score for the respective measures and gender.  
 
Figures 2a and 2b about here 
 
  
21 
 
Table 1. Baseline demographics and clinical characteristics of participants randomized to CBT or TAU (n = 
60). 
 
 CBT TAU 
 (n = 30) (n = 30) 
Age, years at randomisation : mean (SD) 35.7 (9) 36.1 (10.4) 
Gender, male: n (%) 23 (79.3) 18 (60) 
Ethnicity: Non-White: n (%) 16 (53.3) 13 (43.3) 
Level of education: n (%)   
GCSE 3 (10.3) 1 (3.3) 
A Level 19 (65.5) 18 (60) 
Further 7 (24.1) 11 (36.7) 
Marital Status, cohabit:  n (%) 9 (30) 12 (40) 
   
CAADIDa: mean (SD)   
Inattentive 8 (1) 8.1 (1.4) 
Hyperactive/Impulsive 4.6 (2.5) 4.9 (2.3) 
   
 
ADHD Medication: n (%) 
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Yes 19 (63.3) 26 (86.7) 
ADHD Medication Type: n (%)   
Methylphenidate 16 (53.3) 18 (60.0) 
Dexamphetamine 1 (3.3) 7 (23.3) 
Dexamphetamine & 
Modafinil 1 (3.3) 0 (0.0) 
Atomoxetine 1 (3.3) 1 (3.3) 
Other Medication: n (%)   
Yes 3 (10.0) 8 (26.7) 
Other Medication Type: n (%)   
SSRI 2(6.7) 8 (26.7) 
Benzodiazepine 1 (3.3) 0 (0.0) 
a Conners’ Adult ADHD Diagnostic Interview for DSM-IV™(13) 
 
  
23 
 
Table 2. Full unadjusted descriptive statistics (mean, sd and n) for primary and secondary outcome measures at 
baseline, 30 weeks (end of treatment) and 42 weeks (12 weeks after the end of treatment) for TAU vs CBT groups.  
Measure Group Baseline 30 weeks 42 weeks 
  n Mean (SD) n Mean (SD) n Mean (SD) 
CSS Total CBT 30 34.5 (7.5) 27 21.3 (10.6) 27 20.8 (8.8) 
 TAU 30 33.5 (6.1) 19 32.6 (7.8) 17 29.1 (7.5) 
        
CSS Inatt. CBT 30 19.8 (3.1) 27 12.1 (5.9) 27 12.2 (5.6) 
 TAU 30 20.0 (3.5) 19 18.7 (4.9) 17 16.7 (4.7) 
        
CSS Hyp/imp. CBT 30 14.7 (5.8) 27 9.1 (5.7) 27 8.6 (4.2) 
 TAU 30 13.5 (4.9) 19 13.9 (4.7) 18 12.3 (4.3) 
        
WSAS CBT 30 20.0 (8.2) 27 12.8 (8.5) 27 10.2 (6.9) 
 TAU 30 21.8 (8.0) 19 19.2 (8.4) 18 16.8 (8.8) 
        
CSS Informant Total CBT 27 28.1 (9.3) 22 21.0 (11.2) 26 20.0 (10.6) 
 TAU 26 28.3 (9.6) 17 29.2 (10.1) 19 24.7 (10.0) 
        
CSS Informant 
Inatt. 
CBT 
27 16.9 (5.7) 22 11.9 (6.5) 26 11.9 (7.3) 
 TAU 26 16.9 (5.8) 17 17.6 (4.9) 19 15.4 (6.4) 
        
CSS Informant 
Hyp/imp. 
CBT 
27 11.2 (5.9) 22 9.1 (5.9) 26 8.1 (5.3) 
 TAU 26 11.4 (5.2) 17 11.6 (6.0) 20 8.9 (5.3) 
        
HADS Anxiety CBT 29 10.3 (3.5) 27 7.5 (3.5) 27 6.8 (3.6) 
 TAU 30 9.5 (3.9) 19 10.4 (3.6) 19 9.7 (4.0) 
        
HADS Depression CBT 30 5.5 (3.0) 26 3.1 (2.3) 27 3.3 (3.6) 
 TAU 30 6.3 (3.7) 19 6.4 (3.7) 19 5.8 (2.9) 
        
CORE-OM Total CBT 29 40.8 (16.0) 26 29.2 (16.5) 27 26.6 (17.6) 
 TAU 29 43.2 (21.5) 19 44.6 (23.0) 19 40.3 (22.4) 
        
CORE Problems CBT 29 18.3 (7.5) 26 11.6 (7.3) 27 10.9 (7.3) 
 TAU 29 18.1 (9.2) 19 18.5 (10.2) 19 16.7 (9.2) 
        
CORE Functioning CBT 29 15.7 (7.2) 26 13.0 (7.6) 27 11.5 (7.8) 
 TAU 29 18.5 (8.8) 19 18.6 (9.6) 19 16.3 (9.1) 
        
CORE Wellbeing CBT 29 5.9 (2.9) 26 3.9 (3.0) 27 3.6 (3.1) 
 TAU 29 5.7 (3.9) 19 6.4 (4.0) 19 6.3 (4.2) 
        
CORE Risk CBT 26 1.0 (1.7) 26 0.7 (1.7) 27 0.4 (1.5) 
 TAU 19 1.0 (2.6) 19 1.1 (2.1) 19 0.9 (2.3) 
        
        
  Baseline  30 weeks 42 weeks 
CGI     n Improved n 
(%) 
n Improved n 
(%) 
CGI Improvement 
(Participant)  
CBT 
  25 18 (72%) 27 16 (59.3%) 
 TAU   19 1 (5.3%) 18 1 (5.6%) 
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CGI Satisfaction 
(Participant) 
CBT 
  25 23 (92%) 27 24 (89%) 
 TAU   18 4 (22%) 17 4 (24%) 
        
CGI Improvement 
(Blind Assessor) 
CBT 
  28 15 (54%) 26 15 (57.7%) 
 TAU   19 1 (5.3%) 19 0 (0%) 
        
        
         
Abbreviations: CSS – Adult Barkley Current Symptoms Scale (Participant and Informant) total scores with 
inattentive and hyperactive/impulsive symptom subscales, WSAS – Work and Social Adjustment Scale, CGI 
– Clinical Global Impression: Yes / No - (Participant Improvement and Satisfaction, Blind Assessor 
Improvement), HADS – Hospital Anxiety and Depression Subscale, CORE-OM - Clinical Outcomes in 
Routine Evaluation Outcome Measure 
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Table 3. Adjusted mean group differences (CBT versus TAU), test statistics and adjusted effect sizes for primary and secondary outcomes between baseline 
and both 30 weeks and 42 weeks (main outcome point).  
 Adjusted Mean 
Difference† 
(95% CI) 
Test statistic and p 
value 
Adjusted 
Effect 
Size 
Adjusted Mean 
Difference† 
(95% CI) 
Test statistic and p 
value 
Adjusted 
Effect 
Size 
 30 weeks 42 weeks 
Primary Outcomes       
       
CSS 
-10.2  
(-14.25, -10.2) 
F(1, 61.5) = 16.2  
p < 0.001 
-1.52‡ -8.8 
(-13.1, -4.6) 
F(1, 46.8) = 20.3 
 p < 0.001 
-1.31‡ 
       
WSAS -6.6 
(-10.4, -2.8) 
F (1, 50.3) = 11.2 
p = 0.002 
-0.82‡ 
-6.6 
(-10.3, -3.0)  
F(1, 46.9) = 9.8 
p = 0.003 
-0.82‡ 
       
Secondary Outcomes       
CSS Informant -3.94 
(-9.1, -1.2) 
F (1, 50.2) = 2.4 
p = 0.13 
-0.42‡ -3.6 
(-8.6, 1.3) 
F(1, 40.1) = 4.4 
p = 0.14 
-0.38‡ 
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HADS Anxiety -2.21 
(-3.89, -0.52) 
F (1,62.11) = 6.76 
p = 0.012 
-0.60‡ -2.3 
(-3.9, -0.6) 
F(1, 45.6) = 6.4 
p = 0.015 
-0.62‡ 
       
HADS Depression -2.04 
(-3.46, -0.63) 
F (1,64) = 8.24  
p = 0.006 
-0.61‡ -2.2 
(-3.6, -0.8) 
F(1, 46.7) = 10.2  
p = 0.002 
-0.66‡ 
       
CORE-OM Total -9.77 
(-18.49, -1.03) 
- -0.52‡ -9.8 
(-18.3, -1.3) 
- -0.52‡ 
       
CORE Problems -4.7 
(-8.71, -0.7) 
F (1,56.4) = 5.48 
p = 0.023 
-0.58‡ -4.8 
(-8.7, -0.9) 
F(1, 44.9 = 5.34 
p = 0.025 
-0.59‡ 
       
CORE Functioning -2.33 
(-6.01, 1.37) 
F (1,60.9) = 1.59 
p = 0.21 
-0.27‡ -2.3 
(-5.9, 1.3) 
F(1, 44.9) = 2.2 
p = 0.28 
-0.27‡ 
       
CORE Wellbeing -2.25 
(-3.95, -0.54) 
F (1,66.16) = 6.86  
p = 0.011 
-1.03‡ -2.2 
(-3.9, -0.6) 
F(1, 44.7) = 5.8 
p = 0.020 
-1.01‡ 
       
CORE Risk -0.38 
(-1.34, 0.57) 
F (1,66.13) = 0.64 
p = 0.43 
-0.18‡ -0.3 
(-1.2, 0.6) 
F(1, 44.4) = 0.54 
p =0.46 
-0.14‡ 
       
CGI Odds Ratio 
(95%CI) 
Exact p test  Odds Ratio 
(95%CI) 
Exact p test  
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CGI Improvement (Participant) 41.6 
(4.9, 2005) 
p < 0.001 - 23.1 
(2.8, 1089) 
p < 0.001 - 
       
CGI Satisfaction (Participant) 35.0 
(5.4, 429) 
p < 0.001 - 23.2 
(4.1, 190.2) 
p < 0.001 - 
       
CGI Improvement (Blind 
Assessor) 
19.6 
(2.4, 917) 
p < 0.001  ∞ 
(4.7, ∞) 
-  
Abbreviations: CSS –Adult Barkley Current Symptoms Scale (Participant and Informant), WSAS – Work and Social Adjustment Scale, CGI – Clinical Global 
Impression Yes / No - (Participant Improvement and Satisfaction, Blind Assessor Improvement), HADS – Hospital Anxiety and Depression Subscale, CORE-
OM - Clinical Outcomes in Routine Evaluation Outcome Measure. 
† - Estimated group mean differences for treatment (CBT vs TAU) at 42 weeks are adjusted for baseline values of outcome, time-point of visit, interaction 
between treatment and time-point at 30 weeks and gender. 
# - Odds ratio for odds of improvement / satisfaction for CBT relative to TAU. 
‡ - Standardized adjusted effect size is derived from the adjusted group mean difference divided by the baseline standard deviation of the measure. 
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Discussion  
This is the first clinical trial to provide evidence for the effectiveness of formulation-driven CBT in 
adults with ADHD.  As predicted, when added to TAU, CBT had significantly greater success in 
reducing both ADHD symptoms and improving occupational and social functioning than TAU alone 
and the sizes of these effects were large.  At the main outcome point, mean scores on each of the 
primary outcomes for the CBT group had reduced to either below (CSS), or very close to (WSAS) the 
scale thresholds for clinical significance (11, 17).  
 
CBT also provided statistically significantly greater improvements for most secondary outcomes 
including independently-rated CGI Improvement and self-rated anxiety, depression, global distress, 
CGI Improvement and CGI Satisfaction.  Observer ratings of CSS were in the same direction as the 
self-report CSS, however this improvement was not statistically significant.  Perhaps it takes more 
sustained improvement to change others' view of an adult with ADHD.  
 
Our findings are encouraging as they suggest that formulation-driven CBT for adult ADHD is effective 
in reducing not only the core symptoms of the condition but also related impairment and emotional 
distress. All of our functional measures changed after CBT with the exception of the CORE 
Functioning subscale. However, it is also possible that the CORE Functioning subscale, which is a 
generic measure may not be the best measure of functioning and that participation in life specifically 
in relation to ADHD symptoms as assessed by the WSAS, our primary outcome, is more appropriate. 
It is therefore consistent with the NICE recommendations that adult ADHD treatments address 
functioning and emotional distress in addition to the core symptoms.  Furthermore we had 
hypothesised that a benefit of the formulation-driven CBT approach was that it allowed concurrent 
treatment of the emotional impact of ADHD alongside the core symptoms themselves and results 
suggest this is indeed the case.  This is of particular relevance given the high rates of co-morbid 
mood disorders in this patient group.   
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Equivalent use of medication between the two groups suggests the differences in outcomes are 
unlikely to be attributable to ADHD or other psychotropic medication. There were no important 
differences in safety outcomes between the treatments. Levels of adverse events were slightly 
higher in the CBT group. However it is possible that levels of reporting in this group were slightly 
higher since participants were asked about them at every CBT session, as opposed to just at the 
assessment points.  Also, for the three CBT participants who had more than one event, events could 
have been related to each other (i.e. continuation of the original event).   
 
There was a greater degree of engagement in the CBT condition evidenced by the lower loss to 
follow-up in this group.  This is consistent with the participant satisfaction data where a significantly 
higher proportion of participants rated themselves as ‘very satisfied’ or ‘moderately satisfied’ 
compared with the TAU group.  Therefore this study demonstrates that CBT is a highly acceptable 
treatment for patients. 
 
The main outcome was 42 weeks post baseline.  Results were similar at 30 weeks.  Active CBT 
treatment took place up to 30 weeks and results therefore suggest that improvements were 
maintained at 12 weeks following the end of active treatment (see Figures 2 and 3).   
Since this is a proof of concept trial, the effect sizes obtained are not definitive.  However, they 
compare well with other adult ADHD CBT studies.  RCTs of individualised CBT have found effect sizes 
on independently and self-rated ADHD symptom severity to be in the range of 1.2-1.7 when 
comparing individualised CBT with TAU and in the range 0.5-0.6 when comparing individualised CBT 
with relaxation and educational support (4, 5).  Comparing effect sizes across ADHD treatment 
studies more widely, meta-analyses of methylphenidate (the NICE-guideline recommended first-line 
treatment for adult ADHD) compared with placebo have found average effect sizes range from 0.42 
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to 0.9 (22), however the differences in design should be taken into account (particularly active 
treatment comparison). 
 
This study has several limitations.  First, a high number of participants were lost to follow-up in the 
TAU group.  However results of the sensitivity analysis suggest that even when taking this into 
account the treatment effect was robust. 
 
Second the study design does not control for therapist time and attention and we are therefore 
unable to say whether the difference in results between the two treatment groups is due to the CBT 
as opposed to non-specific treatment effects.  
 
Third, owing to resource constraints we were unable to follow up participants for longer to 
investigate whether CBT improved outcomes in the longer term.  However the main outcome was at 
42 weeks and active treatment ended at 30 weeks, so this study provides evidence that the effects 
do extend for at least 12 weeks beyond the end of active treatment. 
 
Fourth there are some issues relating to generalisability of the findings.  We excluded participants 
with an alternative primary diagnosis or severe co-morbidities utilising similar exclusion criteria to 
Safren et al’s previous RCTs of individualised CBT for ADHD.  We used the same exclusion criteria as 
the Safren studies because we wanted to include a similar sample and for the CBT to focus on ADHD 
and associated symptoms as opposed to a separate primary clinical problem.  However, 
individualised formulations can be complex, taking account of several presenting diagnoses so it 
seems likely our formulation driven approach, which has been shown to be effective in reducing 
emotional distress, could be adapted for people with ADHD who have severe co-morbidities.  The 
approach would likely incorporate features of protocols developed for relevant co-morbid conditions 
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while also addressing ADHD-related concerns.  It is notable that while similar co-morbidity exclusion 
criteria were used in this study and the Safren studies, our screen-out rates were considerably 
different.  We believe this is due to the differing referrals to the clinics – our referrals have highly 
variable presentations with many referrals either not receiving an ADHD diagnosis or having one or 
more co-morbidity from the study exclusion criteria.   
 
Fifth we do not know whether different medication status has an effect on the outcomes.  However 
the randomized controlled design controlled for any differences in medication between the two 
groups.  It was unfortunately beyond the scope of the current study to investigate predictors or 
moderators of outcome such as medication. 
 
Our CBT results also apply to people referred to specialist care. Therapists were highly trained and 
experienced and one therapist saw the majority of the cases.  Investigation of the effectiveness of 
this intervention with a broader range of ADHD presentations (e.g. when it is not the primary 
problem) and in less specialist settings is now required. Blinding participants or clinicians to 
treatment allocation was not possible.  The main outcomes were subjective and rated by 
participants.  While this avoided investigator bias it could be subject to other biases.  Expectations of 
treatment were not assessed at baseline so it is not possible to ascertain whether this had an effect.  
In this study ratings by the independent assessor who was blind to treatment allocation were also 
consistent with the self-rated measures. While a commonly used indicator of treatment effects, the 
accuracy of ADHD self-report has been found to be variable across studies (23, 24), however as yet, 
to the authors’ knowledge, no alternative primary outcome measures (such as ‘more objective’ 
executive functioning tests for example) have been found to be more appropriate for psychosocial 
studies of ADHD. 
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This study provides data which can be used to estimate the parameters needed to design a future 
larger trial of formulation-driven CBT for adult ADHD.  We have used appropriate outcome 
measures, defined a priori, which have been sensitive to changes following the interventions.  We 
have established the willingness of participants to be consented and of clinicians to recruit 
participants.  This study has also provided important information as to the number of eligible 
patients in specialist services and numbers lost to follow-up.  Current data suggests future studies 
should aim to broaden the eligibility criteria to increase recruitment rates and generalizability of the 
findings.  The current study suggests loss to follow-up may be more likely in treatment conditions 
involving less contact with a clinician. 
 
Findings from this trial suggest that individually delivered formulation-based CBT when added to 
TAU is more effective than TAU alone in improving core symptoms, functioning and emotional 
distress and that this treatment is highly acceptable to patients.  Future studies should assess the 
effectiveness of the intervention in a larger sample, with a broader range of patients and therapists 
as well as the use of a comparator therapy to control for therapist time and attention. 
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Table 1. Full primary outcome model of CSS score showing effect of treatment at 42 weeks adjusted for 
baseline CCS, time (30 weeks), time by treatment interaction (30 weeks) and, gender. Estimated means are 
shown with standard errors, lower 95% confidence interval, upper 95% confidence interval, F ratios and 
Kenward-Roger degrees of freedom and p-values. 
Parameter Estimate 
Standard 
Error 
Lower 
95% CI 
Upper 
95% CI df F p.KR 
(Intercept) 8.4 5.1 -1.7 18.6 
   
Treatment -8.8 2.1 -13.1 -4.6 50.4 22.0 0.001 
Time (30 weeks) 1.1 1.0 -0.8 3.0 135 0.4 0.509 
Baseline CSS 0.6 0.2 0.3 0.9 50.1 17.5 0.001 
Male 3.5 2.2 -0.9 7.8 50.5 2.5 0.118 
Treatment x Time 
(30 weeks) 
-1.5 1.2 -3.8 0.9 134.9 1.5 0.223 
 
 
Table 2. Full primary outcome model of WSAS showing effect of treatment at 42 weeks adjusted for baseline 
WSAS score, time (30 weeks), time by treatment interaction (30 weeks) and, gender. Estimated means are 
shown with standard errors, lower 95% confidence interval, upper 95% confidence interval, F ratios and 
Kenward-Roger degrees of freedom and p-values. 
Parameter Estimate 
Standard 
Error 
Lower  
95% CI 
Upper  
95% CI df F p.KR 
(Intercept) 4.9 2.9 -0.6 10.4    
Treatment -6.6 1.9 -10.3 -2.9 46.6 9.8 0.003 
Time 30 weeks 0.9 0.7 -0.6 2.3 132.8 12.9 0.000 
Baseline WSAS 0.6 0.1 0.4 0.9 47.9 31.7 0.000 
Male -0.5 2.0 -4.3 3.3 46.6 0.1 0.801 
Treatment x Time 
(30 weeks) 1.7 0.9 -0.2 3.5 132.5 3.2 0.077 
  
37 
 
Table 3. Full Adverse Events Log, participants 1, 3 and 5 had two adverse events recorded. 
 Description of the AE 
Was AE related to 
trial?  
Was AE 
serious? 
CBT    
1a Assaulted definitely unrelated no 
1b Elevated mood uncertain no 
2 
Infection and complications requiring hospital 
treatment following an accident 
definitely unrelated yes 
3a Miscarriage requiring hospital treatment definitely unrelated yes 
3b New episode low mood uncertain no 
4 Relapse in pre-existing medical condition definitely unrelated no 
5a Elevated mood possibly related No 
5b Deterioration in mood uncertain No 
TAU    
1 New episode low mood definitely unrelated no 
2 Attended hospital for operation definitely unrelated no 
3 Assaulted  definitely unrelated no 
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Semi-structured interview for Blind Assessor.  Answers to these questions inform CGI 
rating 
I am going to ask you some questions in order to find out more about how you are at the 
moment.  I don’t know what treatment you received here in the trial and I’m not going to 
ask you anything about it.  It is very important that I should not know which treatment you 
received so that I can be as unbiased as possible.  
If you would like me to repeat the question or clarify what the question means, please ask.  
If you want to stop or take a break, please ask me. 
1) I would like to ask you some questions about your ADHD  
a) ADHD progress 
Overall, how would you say your ADHD is now? 
On the whole, compared with when you started the trial (i.e. not when you first came 
into the service), are you better, worse or about the same? 
Can you give any examples? (e.g.  organisation, procrastination, impulsivity) 
b) School/employment 
When you began the trial were you at school/college/work? 
If yes, was it full-time, part-time, paid/voluntary? 
If no, did your ADHD prevent you from working? 
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How much was your work/study affected by your ADHD at that time? 
At present are you currently working or studying?   
Does your ADHD affect your work/study now? 
c) Social activities 
Before you started the trial, did your ADHD affect social activities?  E.g. going out, 
talking to people? 
Has this changed at all? 
d) Mood 
What was your mood like before you started the trial(e.g. low mood, stress, anxiety)? 
Have you noticed any changes in your mood? 
e) View of ADHD 
Has your view of ADHD changed at all? If so, in what way? 
f) Other 
Have there been any other changes that we haven’t covered? 
Is there anything else that you would like to mention that we haven’t covered? 
 
 
 
